Canaccord Genuity Group Increases Atara Biotherapeutics (NASDAQ:ATRA) Price Target to $21.00

Atara Biotherapeutics (NASDAQ:ATRA) had its price target hoisted by Canaccord Genuity Group from $13.00 to $21.00 in a research note released on Wednesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on ATRA. The Goldman Sachs Group decreased their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.67.

Atara Biotherapeutics Trading Down 6.0 %

NASDAQ ATRA opened at $12.00 on Wednesday. The stock has a market cap of $69.12 million, a PE ratio of -0.47 and a beta of 0.50. The company’s 50-day moving average price is $9.00 and its 200-day moving average price is $10.23. Atara Biotherapeutics has a 12 month low of $6.50 and a 12 month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same quarter last year, the firm earned ($16.50) EPS. As a group, sell-side analysts forecast that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. State Street Corp boosted its holdings in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the period. FMR LLC increased its holdings in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $79,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.